UA79235C2 - Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition - Google Patents

Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition Download PDF

Info

Publication number
UA79235C2
UA79235C2 UA2003109084A UA2003109084A UA79235C2 UA 79235 C2 UA79235 C2 UA 79235C2 UA 2003109084 A UA2003109084 A UA 2003109084A UA 2003109084 A UA2003109084 A UA 2003109084A UA 79235 C2 UA79235 C2 UA 79235C2
Authority
UA
Ukraine
Prior art keywords
avr
cells
bek
biu
iem
Prior art date
Application number
UA2003109084A
Other languages
English (en)
Ukrainian (uk)
Inventor
Charles Dinarello
Soo Khiun Kim
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of UA79235C2 publication Critical patent/UA79235C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
UA2003109084A 2001-03-08 2002-08-03 Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition UA79235C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27432701P 2001-03-08 2001-03-08
PCT/IB2002/002344 WO2002101049A2 (en) 2001-03-08 2002-03-08 Interleukin-18 mutants, their production and use

Publications (1)

Publication Number Publication Date
UA79235C2 true UA79235C2 (en) 2007-06-11

Family

ID=23047735

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003109084A UA79235C2 (en) 2001-03-08 2002-08-03 Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition

Country Status (19)

Country Link
US (2) US7524488B2 (da)
EP (1) EP1392830B1 (da)
JP (1) JP2004530432A (da)
KR (1) KR100862136B1 (da)
CN (1) CN100503829C (da)
AT (1) ATE315647T1 (da)
AU (1) AU2002324249B2 (da)
BR (1) BRPI0207933B8 (da)
CA (1) CA2438851C (da)
DE (1) DE60208692T2 (da)
DK (1) DK1392830T3 (da)
EA (1) EA005769B1 (da)
ES (1) ES2251610T3 (da)
HK (1) HK1084151A1 (da)
IL (2) IL157800A0 (da)
MX (1) MXPA03008110A (da)
SI (1) SI1392830T1 (da)
UA (1) UA79235C2 (da)
WO (1) WO2002101049A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
ATE360647T1 (de) * 2003-11-05 2007-05-15 Ares Trading Sa Verfahren zur aufreinigung von il-18-bindendem protein
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
US7691611B2 (en) 2005-06-03 2010-04-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
JP5091127B2 (ja) 2005-06-10 2012-12-05 アレス トレーディング ソシエテ アノニム Il−18結合タンパク質の精製のための方法
CN101177454B (zh) * 2007-05-09 2010-09-22 郑骏年 Il-18突变体多肽及制备及用途
WO2012078936A2 (en) * 2010-12-10 2012-06-14 Glaxosmithkline Llc Methods to produce a purified peptide chain fraction
IL305370A (en) * 2017-09-06 2023-10-01 Univ Yale Variants of interleukin-18 and methods of use
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
JP2021170968A (ja) * 2020-04-22 2021-11-01 国立大学法人 長崎大学 マウスil−18の製造方法及びそのための組換えdna
KR20230052956A (ko) * 2020-08-19 2023-04-20 브라이트 피크 테라퓨틱스 아게 변형된 il-18 폴리펩티드 및 이의 용도
EP4236990A1 (en) 2020-11-02 2023-09-06 Simcha Il-18, Inc. Interleukin-18 variants and methods of use
EP4293039A1 (en) * 2021-02-10 2023-12-20 Nagasaki University Novel human interleukin-18 variant and use therefor
US20230146665A1 (en) 2021-07-27 2023-05-11 Xencor, Inc. Il-18-fc fusion proteins
JP2023024168A (ja) 2021-08-06 2023-02-16 国立大学法人 長崎大学 がんの治療剤
WO2023056193A2 (en) * 2021-09-29 2023-04-06 Chimera Bioengineering, Inc. Il-18 variants and uses thereof
WO2023118497A1 (en) * 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
US20240116997A1 (en) 2022-02-23 2024-04-11 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
AU2023224445A1 (en) * 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Modified il-18 polypeptides
AU2023226512A1 (en) * 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
IL129427A0 (en) 1999-04-13 2000-02-17 Yeda Res & Dev Preparation of biologically active molecules

Also Published As

Publication number Publication date
EP1392830B1 (en) 2006-01-11
BR0207933A (pt) 2004-03-02
WO2002101049A3 (en) 2003-12-18
US7875709B2 (en) 2011-01-25
DE60208692T2 (de) 2006-07-13
EA005769B1 (ru) 2005-06-30
EA200300987A1 (ru) 2004-02-26
IL157800A0 (en) 2004-03-28
WO2002101049A2 (en) 2002-12-19
KR100862136B1 (ko) 2008-10-09
EP1392830A2 (en) 2004-03-03
JP2004530432A (ja) 2004-10-07
ATE315647T1 (de) 2006-02-15
IL157800A (en) 2009-08-03
DK1392830T3 (da) 2006-05-08
AU2002324249B2 (en) 2007-04-05
BRPI0207933B1 (pt) 2020-11-24
SI1392830T1 (sl) 2006-06-30
CN100503829C (zh) 2009-06-24
US20090286855A1 (en) 2009-11-19
US7524488B2 (en) 2009-04-28
KR20030088448A (ko) 2003-11-19
US20020169291A1 (en) 2002-11-14
CA2438851C (en) 2011-07-26
MXPA03008110A (es) 2003-12-12
BRPI0207933B8 (pt) 2021-05-25
CA2438851A1 (en) 2002-12-19
ES2251610T3 (es) 2006-05-01
HK1084151A1 (en) 2006-07-21
CN1764723A (zh) 2006-04-26
DE60208692D1 (de) 2006-04-06

Similar Documents

Publication Publication Date Title
UA79235C2 (en) Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition
Chen et al. T-cell immunity to the joining region of p210BCR-ABL protein.
Morgan et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma
CA2906587C (en) Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
CN108504668A (zh) 靶向cd19和cd22嵌合抗原受体及其用途
EP3842051A1 (en) Therapeutic agent comprising nucleic acid and car-modified immune cell and application thereof
CN101835892A (zh) Cdca1肽和包含cdca1肽的药剂
CN109320615A (zh) 靶向新型bcma的嵌合抗原受体及其用途
Valencia et al. Interleukin-2 as immunotherapeutic in the autoimmune diseases
CN113727720A (zh) 用于治疗表达cldn6的癌症的嵌合抗原受体修饰的细胞
US20080125390A1 (en) Methods for Modulating Immune and Inflammatory Responses
CN109423495A (zh) 一种双靶向嵌合抗原受体及其用途
CN108866088A (zh) 靶向cll-1嵌合抗原受体及其用途
US11098283B2 (en) T cells modified to overexpress c-Myb
Xu et al. Interleukins in the treatment of melanoma
AU2006327514B2 (en) DNA vaccine for cancer therapy
CN116970058B (zh) 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用
US20240018213A1 (en) Modulators of notch signaling and methods of use thereof
KR20220052987A (ko) Ebv 유래 항원에 특이적인 tcr 작제물
EP3683229A1 (en) Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy
US20240009239A1 (en) Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy
US20230340063A1 (en) Optimization of chimeric antigen receptor
CN108424458A (zh) 靶向ny-eso-1的嵌合抗原受体及其用途
CN108864276A (zh) 靶向ny-eso-1的t细胞受体联合表达pd1抗体可变区及其用途
Lázaro‐Gorines et al. Dendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2